Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

BeiGene (Ridgefield Park) Co., Ltd.

1 abstract

Abstract
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 European/North American (EU/NA) subgroup.
Org: BeiGene (Ridgefield Park) Co., Ltd., BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene Co., Ltd.,